|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Tom DiLenge |
Date | 4/20/2016 9:59:24 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
EPA Regulations on Biotechnology
--Reauthorization of Pesticide Registration Improvement Act (PRIA)
--EPA Points to Consider Guidance Document for GE Algae
Review of the Federal Coordinated Framework for Biotechnology Products
USDA/APHIS Agricultural Biotechnology Regulations
--Efficient Science-Based Review of Biotech Products
--USDA Decision on GE Crops Environmental Impact Statement
--Co-existence of Production Systems
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Foreign Agricultural Biotechnology Laws and Regulations
--EU Ag-Biotech Policies and Regulations
--China Biotechnology Regulations
--Asynchrony of International Approvals
--Like-minded Countries Initiatives
--Korea Biotechnology Regulations
Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--U.S. Government Policy
--S.2609: The Biotech Labeling Solutions Act
Adventitious Presence (Low Level Presence)
--International Low Level Presence Policies
Funding for the USDA
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Genetically Engineered (GE) Animals
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
--Labeling
--One Health Legislation (Senate Discussion Draft)
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
--FDA Approval
Funding for Biomass Crop Assistance Program
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
TransAtlantic Trade and Investment Partnership
--Ag-Biotech Issues
17. House(s) of Congress and Federal agencies Check if None
Environmental Protection Agency (EPA), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Brian |
Baenig (House and Senate Only) |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
OMara |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
--Labeling
--One Health Legislation (Senate Discussion Draft)
--FDA Approval
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for the USDA
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for Biomass Crop Assistance Program
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for FDA
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for Centers for Disease Control and Prevention Vaccine Programs
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for National Institutes of Health
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for Biofuels
--Department of Defense Funding of Advanced Biofuels
--Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Funding for Renewable Chemicals/Bio-based Products
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Energy Basic Research Funding
--Advanced Research Projects Agency
--DOE Office of Science
--Energy and Water Development and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Tracey |
LaTurner |
|
|
|
Kathleen |
Holcombe |
|
|
|
Amy |
Walker |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Nicolas |
Magallanes |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Renewable Chemicals/Bio-based Products (Non-Funding)
--Nomenclature Usage
--S. 2271: The Renewable Chemicals Act
--S. 1656/H.R. 2883: Master Limited Partnership Parity Act
--H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
--H.R. 2576: TSCA Modernization Act
--S.697: Frank R. Lautenberg Chemical Safety for the 21st Century Act
--Implementation of the Agricultural Act of 2014
--Reauthorization of USDA Bio-Preferred Program
--Investment Tax Credit for Renewable Chemicals and Bio-based Products
EPA Regulations on Biotechnology
--Reauthorization of Pesticide Registration Improvement Act (PRIA)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Rina Singh |
Singh |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Dana |
O'Brien |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
--Labeling
--One Health Legislation (Senate Discussion Draft)
--FDA Approval
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--S.2609: The Biotech Labeling Solutions Act
--U.S. Government Policy
USDA/APHIS Agricultural Biotechnology Regulations
--Efficient Science-Based Review of Biotech Products
--USDA Decision on GE Crops Environmental Impact Statement
--Co-existence of Production Systems
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Biosimilars
--Implementation of Affordable Care Act
--Interchangeability and Pharmacy Substitution
--Naming
--Brazil Biologics Regulations
Drug Importation
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
OBrien |
|
|
|
Nicolas |
Magallanes |
|
|
|
Deborah |
Shelton |
|
|
|
Scott |
McGoohan |
|
|
|
Kathleen |
Holcombe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
TransPacific Partnership
--Data and Intellectual Property Protection for Pharmaceuticals
Patent Reform
--H.R. 9: Innovation Act
--S.1137: The PATENTS Act of 2015
Bayh-Dole Act/Tech Transfer
--Commercialization of Federally Funded Research Initiative
--March-In Rights
Intellectual Property International Enforcement
Pacific Alliance IP Harmonization
Inter Partes Review
--Implementation of the American Invents Act of 2011
--S. 1137: The PATENTS Act of 2015
World Trade Organization - Special 301 Submissions
--Middle East Issues
--Latin American Issues
--Canada Issues
UN Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Natl Institutes of Health (NIH), Commerce - Dept of (DOC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jamie |
Gregorian |
|
|
|
Charles |
Fritts |
|
|
|
Hans |
Sauer |
|
|
|
Cartier |
Esham |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
EPA Regulation of Biotechnology
--EPA Points to Consider Guidance Document for GE Algae
Energy Basic Research Funding
--Advanced Research Projects Agency
--DOE Office of Science
--Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Funding for Biofuels
--Department of Defense Funding of Advanced Biofuels
--Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Renewable Fuel Standard
--The 2014-2016 Final Rule
--Departments of Interior, and Related Agencies Appropriations Act for FY 2017
Review of the Federal Coordinated Framework for Biotechnology Products
Renewable Chemicals/Bio-based Products (Non-Funding)
--Implementation of the Agricultural Act of 2014
--Investment Tax Credit for Renewable Chemicals and Bio-based Products
--Nomenclature Usage
--Reauthorization of USDA Bio-Preferred Program
--S. 2271: The Renewable Chemicals Act
--S. 1656/H.R. 2883: Master Limited Partnership Parity Act
--H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
--H.R. 2576: TSCA Modernization Act
--S.697: Frank R. Lautenberg Chemical Safety for the 21st Century Act
Biofuels (Non-Funding)
--Production Tax Credit Extension
--S. 1239/H.R. 1736: to amend the Clean Air Act with respect to the ethanol waiver for the Reid vapor pressure limitations under that Act
--S. 2658: Federal Aviation Administration Reauthorization Act of 2016
----Franken-Grassley Amendment
Funding for Biomass Crop Assistance Program
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
--Labeling
--One Health Legislation (Senate Discussion Draft)
--FDA Approval
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--U.S. Government Policy
--S.2609: The Biotech Labeling Solutions Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
EPA Regulation of Biotechnology
--EPA Points to Consider Guidance Document for GE Algae
Energy Basic Research Funding
--Advanced Research Projects Agency
--DOE Office of Science
--Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Funding for Biofuels
--Department of Defense Funding of Advanced Biofuels
--Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Renewable Fuel Standard
--The 2014-2016 Final Rule
--Departments of Interior, and Related Agencies Appropriations Act for FY 2017
Review of the Federal Coordinated Framework for Biotechnology Products
Renewable Chemicals/Bio-based Products (Non-Funding)
--Implementation of the Agricultural Act of 2014
--Investment Tax Credit for Renewable Chemicals and Bio-based Products
--Nomenclature Usage
--Reauthorization of USDA Bio-Preferred Program
--S. 2271: The Renewable Chemicals Act
--S. 1656/H.R. 2883: Master Limited Partnership Parity Act
--H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
--H.R. 2576: TSCA Modernization Act
--S.697: Frank R. Lautenberg Chemical Safety for the 21st Century Act
Biofuels (Non-Funding)
--Production Tax Credit Extension
--S. 1239/H.R. 1736: to amend the Clean Air Act with respect to the ethanol waiver for the Reid vapor pressure limitations under that Act
--S. 2658: Federal Aviation Administration Reauthorization Act of 2016
----Franken-Grassley Amendment
Funding for Biomass Crop Assistance Program
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Erick |
Lutt |
|
|
|
Dana |
OBrien |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Brian |
Baenig (House and Senate Only) |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Biosimilars
--Coding
--Implementation of Affordable Care Act
--Interchangeability and Pharmacy Substitution
--Naming
--Patent Certification
--Brazil Biologics Regulations
Funding for National Institutes of Health
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for Centers for Disease Control and Prevention Vaccine Programs
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
340B Drug Pricing Program
--Implementation of Affordable Care Act
--Program Implementation & Oversight
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Medicaid Pricing and Rebates
--Average Manufacturer Price Calculations
--Implementation of Affordable Care Act
Drug Importation
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Diagnostics and Personalized Medicine Regulation and Oversight
Funding for FDA
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Biodefense Research, Development and Procurement Issues (Nonfunding)
Reimbursement for Innovative Products
--Medicare Part B Physician-Administered Products
--Medicare Part D Prescription Drug Program:
----CMS Proposed Rule on Protected Classes
--Value-based Contracting and Communications
Drug Evaluation and Review
--Compassionate Use/Expanded Access
--FDA Proposed Rule on Changes to Drug Labeling
--Implementation of the FDA Safety and Innovation Act
--Reauthorization of the Prescription Drug User Fee Act
--Special Medical Use/Limited Population Drug
---- ADAPT Act (House Discussion Draft)
Senate Innovation for Healthier Americans
--Biomarkers and Regulatory Science Improvements
--Expanded Access to Investigational Drugs
--Expedited Pathways
--FDA Hiring Flexibility
--FDA Management and Financial Accountability
--Innovation Incentives
--Longitudinal Study of Chronic Diseases
--Patient Access to Approved Drugs
--Patient-Focused Drug Development
--Use of Real-World Evidence
--Vaccine and Anti-Microbial Resistance Product Development and Incentives
----S. 195: PATH Act
--Communication with Healthcare Professionals and Payors
--Priority Review Voucher Programs
Priority Review of Generic Drugs
----S. 2615: Increasing Competition in Pharmaceuticals Act
Vaccines and Infectious Diseases - General
Government Price Reporting
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Gene Editing Technologies
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Precision Medicine Initiative
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Antibiotic & Diagnostic Tax Credit
--H.R. 3539: Antibiotic & Diagnostic Innovation Act
Drug Manufacturing, Quality & Distribution
--Supply Chain Integrity and Traceability
Affordable Care Act Implementation
--Third Party Support of Patient Premiums and Cost-Sharing Obligations
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
Vaccine Access/Financing
--Adult Immunization (Senate Discussion Draft)
--Implementation of Affordable Care Act
--Senate Chronic Care Working Group Proposals
--Vaccine Injury Compensation Program
TransPacific Partnership
--Data and Intellectual Property Protection for Pharmaceuticals
--Reimbursement Transparency
Orphan Drug Act Tax Credit
UN Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laurel |
Todd |
|
|
|
Joseph |
Damond |
|
|
|
Catharine |
Harris |
|
|
|
Deborah |
Shelton |
|
|
|
Scott |
McGoohan |
|
|
|
Nicolas |
Magallanes |
|
|
|
Kathleen |
Holcombe |
|
|
|
Tracey |
LaTurner |
|
|
|
Amy |
Walker |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Jamie |
Gregorian |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Tracey |
LaTurner |
|
|
|
Sarah |
Kyle |
|
|
|
Tom |
DiLenge |
|
|
|
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Nonfunding)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Nicolas |
Magallanes |
|
|
|
Tracey |
LaTurner |
|
|
|
Amy |
Walker |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Biodefense Research, Development and Procurement Issues
Senate Innovation for Healthier Americans
--Longitudinal Study of Chronic Diseases
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Gene Editing Technologies
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Precision Medicine Initiative
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Amy |
Walker |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Kathleen |
Holcombe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Scott |
McGoohan |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Pricing and Rebates
--Average Manufacturer Price Calculations
--Implementation of Affordable Care Act
Reimbursement for Innovative Products
--Medicare Part B Physician-Administered Products
--Medicare Part D Prescription Drug Program:
----CMS Proposed Rule on Protected Classes
--Value-based Contracting and Communications
Government Price Reporting
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Senate Innovation for Healthier Americans
--Patient Access to Approved Drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Deborah |
Shelton |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Nicolas |
Magallanes |
|
|
|
Sarah |
Kyle |
|
|
|
Laurel |
Todd |
|
|
|
Jamie |
Gregorian |
|
|
|
Tracey |
LaTurner |
|
|
|
Kathleen |
Holcombe |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
--PCAOB Audit Cost Increases
--H.R. 4139: Fostering Innovation Act
XBRL Exemption for Small Public Companies
--H.R. 1965: Small Company Disclosure Simplification Act
--H.R. 1675: Capital Markets Improvement Act
Capital Market Enhancements
--H.R. 1675: Encouraging Employee Ownership Act
--H.R. 4168: Small Business Capital Formation Enhancement Act
--H.R. 3784: Securities & Exchange Commission Small Business Advocate Act
--H.R. 1675: Capital Markets Improvement Act
--H.R. 2354: Streamlining Excessive and Costly Regulations Review Act
--H.R. 4638: Main Street Growth Act
Proxy Advisory Services
--Impact of Policies on Small Public Companies
--Proxy Advisory Firm Reform Act (Discussion Draft)
Reform of SEC Regulation D
--S. 978/H.R. 4498: HALOS Act
Short Selling Transparency
Capital Formation Investment Incentives
--H.R. 2179: PARTNER Act
--Reform of Capital Gains Rules
--Reform of Net Operating Loss Rules
--Reform of Passive Loss Rules
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels (Non-Funding)
--Production Tax Credit Extension
--S. 2658: Federal Aviation Administration Reauthorization Act of 2016
----Franken-Grassley Amendment
Research & Development Tax Credit Reforms
--Extension
--Permanency
--Refundable R&D Credit
Capital Formation Investment Incentives
--H.R. 2179: PARTNER Act
--Reform of Capital Gains Rules
--Reform of Net Operating Loss Rules
--Reform of Passive Loss Rules
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act
Tax Reform
--Innovation Box / Patent Box
Orphan Drug Act Tax Credit
Antibiotic & Diagnostic Tax Credit
--H.R. 3539: Antibiotic & Diagnostic Innovation Act
Inversions
--Financial Services and General Government Appropriations Act for FY 2017
Renewable Chemicals/Bio-based Products (Non-Funding)
--Investment Tax Credit for Renewable Chemicals and Bio-based Products
--S. 2271: The Renewable Chemicals Act
--S. 1656/H.R. 2883: Master Limited Partnership Parity Act
--H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Charles |
Crain |
|
|
|
Tracey |
LaTurner |
|
|
|
Rina |
Singh |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
TransPacific Partnership
--Data and Intellectual Property Protection for Pharmaceuticals
--Reimbursement Transparency
Foreign Agricultural Biotechnology Laws and Regulations
--Asynchrony of International Approvals
--China Biotechnology Regulations
--EU Ag-Biotech Policies and Regulations
--Korea Biotechnology Regulations
--Like-minded Countries Initiatives
Biosimilars
--Brazil Biologics Regulations
Drug Importation
--Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
--Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Pacific Alliance IP Harmonization
Transatlantic Trade and Investment Partnership
--Ag-Biotech Issues
UN Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joseph |
Damond |
|
|
|
Jamie |
Gregorian |
|
|
|
Charles |
Fritts |
|
|
|
Matthew |
OMara |
|
|
|
Dana |
OBrien |
|
|
|
Nicolas |
Magallanes |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
SCI |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |